AGL 34.90 Decreased By ▼ -0.30 (-0.85%)
AIRLINK 127.45 Increased By ▲ 4.22 (3.42%)
BOP 5.15 Increased By ▲ 0.11 (2.18%)
CNERGY 3.84 Decreased By ▼ -0.07 (-1.79%)
DCL 8.00 Decreased By ▼ -0.15 (-1.84%)
DFML 44.30 Increased By ▲ 0.08 (0.18%)
DGKC 74.70 Increased By ▲ 0.35 (0.47%)
FCCL 24.60 Increased By ▲ 0.13 (0.53%)
FFBL 43.68 Decreased By ▼ -4.52 (-9.38%)
FFL 8.89 Increased By ▲ 0.11 (1.25%)
HUBC 141.45 Decreased By ▼ -4.40 (-3.02%)
HUMNL 10.50 Decreased By ▼ -0.35 (-3.23%)
KEL 3.95 Decreased By ▼ -0.05 (-1.25%)
KOSM 7.84 Decreased By ▼ -0.16 (-2%)
MLCF 32.59 Decreased By ▼ -0.21 (-0.64%)
NBP 56.49 Decreased By ▼ -0.66 (-1.15%)
OGDC 142.27 Decreased By ▼ -3.08 (-2.12%)
PAEL 25.40 Decreased By ▼ -0.35 (-1.36%)
PIBTL 5.80 Increased By ▲ 0.04 (0.69%)
PPL 111.35 Decreased By ▼ -5.45 (-4.67%)
PRL 23.96 Decreased By ▼ -0.04 (-0.17%)
PTC 11.08 Increased By ▲ 0.03 (0.27%)
SEARL 58.44 Increased By ▲ 0.03 (0.05%)
TELE 7.49 No Change ▼ 0.00 (0%)
TOMCL 41.15 Increased By ▲ 0.05 (0.12%)
TPLP 8.75 Increased By ▲ 0.44 (5.29%)
TREET 15.10 Decreased By ▼ -0.10 (-0.66%)
TRG 54.41 Decreased By ▼ -0.79 (-1.43%)
UNITY 27.80 Decreased By ▼ -0.05 (-0.18%)
WTL 1.30 Decreased By ▼ -0.04 (-2.99%)
BR100 8,555 Decreased By -16.4 (-0.19%)
BR30 26,642 Decreased By -634.2 (-2.33%)
KSE100 81,594 Increased By 135 (0.17%)
KSE30 25,803 Increased By 3.5 (0.01%)

Regulatory agencies will be needed to oversee the use of stem cells when current experimental therapies are ready to be tested in humans, scientists said on Tuesday.
They told a meeting on the ethical, legal and social issues surrounding stem cell research that the potential new treatments for illnesses ranging from heart disease and diabetes to Alzheimer's and Parkinson's are still 5 to 15 years away.
But how stem cell therapy will be used in humans and its safety and therapeutic benefits must be looked at very carefully.
"You need to have regulation that is appropriate," said Dr Stephen Minger, a leading stem cell researcher at King's College London.
"It needs to be assessed rigorously long before we go into human patients simply because it is an unproven technology and we have no experience putting these cells into patients," he added.
Professor Martin Evans, of the University of Cardiff in Wales said an international, rather than local or national agencies, may be needed.
Stem cells are master cells in the body that can develop into any cell type. Scientists believe they could act as a type of repair system for the body.
But their use is controversial because the most promising stem cells for treating human diseases are derived from very early human embryos left over from fertility treatments.
Embryonic stem cell research involves the destruction of embryos. In the United States, federal funds for experiments using embryonic stem cells are restricted.
Professor Jan Helge Solbakk, of the University of Oslo in Norway, told the meeting of researchers, patient groups and policy makers that countries which allow fertility treatments but ban embryonic stem cell research should export their spare embryos to nations that do.
"My message to these countries ... is that one cannot continue to ban this research while at the same time silently accepting it will import any future therapies. That is a kind of double standard," said Solbakk.
Minger said he supported Solbakk's suggestion.
"Embryos are in short supply. That is one of the major stumbling blocks in the research," he added.
The sourcing of donated embryos and eggs to create cloned human embryos for stem cell research is a sensitive issue.
Professor Kwang Woo-suk, the scientist at Seoul National University in South Korea who created stem cells with a patient's specific genetic material from cloned embryos, said on Monday his work met government guidelines on ethics.
His comments followed US newspaper reports saying a US scientist suspended collaboration with him over rumours that he had used eggs in the ground-breaking research from a junior scientist in his lab.
Professor Peter Braude, of King's College London, said sourcing of donated eggs for stem cell research poses questions of supply and ethics that need to be addressed.

Copyright Reuters, 2005

Comments

Comments are closed.